Antibe Therapeutics Inc.

Summary:

• Antibe Therapeutics is aiming its unique drug platform at two of the world’s major medical challenges: pain and opioid dependency. Based on groundbreaking science, the platform exploits the anti-inflammatory properties of hydrogen sulfide, a substance now known to be produced and used in every cell in the body.

• Antibe’s lead drug, otenaproxesul, is a novel oral non-opioid for acute pain.The drug’s Phase II trial is set to start in calendar Q1 2024 with top-line data expected in Q3 2024. With no novel oral painkillers introduced in nearly 25 years, demand is growing for alternatives to opioids for treating post-operative pain, acute musculoskeletal pain, dental pain and a range of other acute pain indications. The company’s hydrogen sulfide platform offers therapeutic potential in a wide array of indications — its next target area is inflammatory bowel disease.